{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 444484151
| IUPAC_name = 4-(2-methyl-1''H''-imidazol-1-yl)-2,2-diphenylbutanamide
| image = Imidafenacin.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 170105-16-5
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 53366
| PubChem = 6433090
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XJR8Y07LJO
| KEGG_Ref = {{keggcite|changed|kegg}}
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4938278
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = SQKXYSGRELMAAU-UHFFFAOYSA-N

<!--Chemical data-->
| chemical_formula =  
| C=20 | H=21 | N=3 | O=1 
| molecular_weight = 319.40 g/mol
| smiles = CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N
}}

'''Imidafenacin''' ([[International Nonproprietary Name|INN]]) is a [[urinary]] [[antispasmodic]] of the [[anticholinergic]] class. Its molecular weight is 319.40 g/mol

==References==
*{{cite journal |vauthors=Kobayashi F, Yageta Y, Segawa M, Matsuzawa S |title=Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland |journal=Arzneimittelforschung |volume=57 |issue=2 |pages=92–100 |year=2007 |pmid=17396619 |doi= 10.1055/s-0031-1296589|url=}}
*{{cite journal |vauthors=Miyachi H, Kiyota H, Uchiki H, Segawa M |title=Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents |journal=Bioorg. Med. Chem. |volume=7 |issue=6 |pages=1151–61 |date=June 1999 |pmid=10428387 |doi= 10.1016/S0968-0896(99)00003-6|url=http://linkinghub.elsevier.com/retrieve/pii/S0968-0896(99)00003-6}}

{{Urologicals}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic antagonists]]
[[Category:Imidazoles]]
[[Category:Carboxamides]]


{{genito-urinary-drug-stub}}